Although the specific mechanism by which PCDHGB7 participates in DNA MMR requires further exploration, the clinical significance of this phenomenon will grow with the extensive investigation into DNA damage repair inhibitors, such as poly-ADP ribose polymerase inhibitors, in patients with NSCLC (37). Here, PCDHGB7 is linked to non-small cell lung carcinoma.